CAR-T for multiple myeloma: practice pearls.

IF 4.5 2区医学 Q1 HEMATOLOGY

Bone Marrow Transplantation Pub Date : 2025-04-17 DOI:10.1038/s41409-025-02582-6

Daniel O'Leary, Veronika Bachanova

引用次数: 0

Abstract

The CAR-T cell products ciltacabtagene autoleucel and idecabtagene vicleucel have transformed the management of patients with multiple myeloma. Here, we present a practical guide highlighting clinical pearls on the incorporation of CAR-T into clinical practice. Topics addressed include expected outcomes, recommendations for referral timing, bridging therapy, treatment complications, therapeutic sequencing, and management of relapse.

查看原文本刊更多论文

CAR-T治疗多发性骨髓瘤：练珍珠。

CAR-T细胞产品ciltactagene autoeucel和idedecabtagene vicleucel已经改变了多发性骨髓瘤患者的治疗。在这里，我们提出了一份实用指南，重点介绍了将CAR-T纳入临床实践的临床要点。讨论的主题包括预期结果、推荐转诊时间、桥接治疗、治疗并发症、治疗顺序和复发管理。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Bone Marrow Transplantation 医学-免疫学

CiteScore

8.40

自引率

8.30%

发文量

337

审稿时长

6 months

期刊介绍： Bone Marrow Transplantation publishes high quality, peer reviewed original research that addresses all aspects of basic biology and clinical use of haemopoietic stem cell transplantation. The broad scope of the journal thus encompasses topics such as stem cell biology, e.g., kinetics and cytokine control, transplantation immunology e.g., HLA and matching techniques, translational research, and clinical results of specific transplant protocols. Bone Marrow Transplantation publishes 24 issues a year.